203 related articles for article (PubMed ID: 25873087)
21. Colorectal cancer susceptibility loci in a population-based study: Associations with morphological parameters.
Ghazi S; von Holst S; Picelli S; Lindforss U; Tenesa A; Farrington SM; Campbell H; Dunlop MG; Papadogiannakis N; Lindblom A;
Am J Pathol; 2010 Dec; 177(6):2688-93. PubMed ID: 21119214
[TBL] [Abstract][Full Text] [Related]
22. MTHFR Glu429Ala and ERCC5 His46His polymorphisms are associated with prognosis in colorectal cancer patients: analysis of two independent cohorts from Newfoundland.
Negandhi AA; Hyde A; Dicks E; Pollett W; Younghusband BH; Parfrey P; Green RC; Savas S
PLoS One; 2013; 8(4):e61469. PubMed ID: 23626689
[TBL] [Abstract][Full Text] [Related]
23. CDH1 promoter polymorphism (-347G-->GA) is a possible prognostic factor in sporadic colorectal cancer.
Zou XP; Dai WJ; Cao J
World J Gastroenterol; 2009 Nov; 15(42):5340-5. PubMed ID: 19908344
[TBL] [Abstract][Full Text] [Related]
24. Genome-Wide miRNA Analysis Identifies miR-188-3p as a Novel Prognostic Marker and Molecular Factor Involved in Colorectal Carcinogenesis.
Pichler M; Stiegelbauer V; Vychytilova-Faltejskova P; Ivan C; Ling H; Winter E; Zhang X; Goblirsch M; Wulf-Goldenberg A; Ohtsuka M; Haybaeck J; Svoboda M; Okugawa Y; Gerger A; Hoefler G; Goel A; Slaby O; Calin GA
Clin Cancer Res; 2017 Mar; 23(5):1323-1333. PubMed ID: 27601590
[No Abstract] [Full Text] [Related]
25. Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.
Tokunaga R; Cao S; Naseem M; Lo JH; Battaglin F; Puccini A; Berger MD; Soni S; Millstein J; Zhang W; Stintzing S; Loupakis F; Cremolini C; Heinemann V; Falcone A; Lenz HJ
Clin Colorectal Cancer; 2019 Mar; 18(1):e8-e19. PubMed ID: 30293873
[TBL] [Abstract][Full Text] [Related]
26. Genetic variation in microRNA-binding site and prognosis of patients with colorectal cancer.
Kim JG; Chae YS; Lee SJ; Kang BW; Park JY; Lee EJ; Jeon HS; Park JS; Choi GS
J Cancer Res Clin Oncol; 2015 Jan; 141(1):35-41. PubMed ID: 25079514
[TBL] [Abstract][Full Text] [Related]
27. The epithelial cadherin -160C/A polymorphism is associated with decreased risk of colorectal cancer: a case-control study.
Li W; Xiao D; Wu H; Xu L
Clin Exp Med; 2020 Feb; 20(1):73-78. PubMed ID: 31625007
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy.
Matsusaka S; Hanna DL; Cao S; Zhang W; Yang D; Ning Y; Sunakawa Y; Okazaki S; Berger MD; Miyamato Y; Parekh A; Stintzing S; Loupakis F; Lenz HJ
Clin Cancer Res; 2016 Jul; 22(13):3218-26. PubMed ID: 26839145
[TBL] [Abstract][Full Text] [Related]
29. Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer.
; Houlston RS; Webb E; Broderick P; Pittman AM; Di Bernardo MC; Lubbe S; Chandler I; Vijayakrishnan J; Sullivan K; Penegar S; ; Carvajal-Carmona L; Howarth K; Jaeger E; Spain SL; Walther A; Barclay E; Martin L; Gorman M; Domingo E; Teixeira AS; ; Kerr D; Cazier JB; Niittymäki I; Tuupanen S; Karhu A; Aaltonen LA; Tomlinson IP; Farrington SM; Tenesa A; Prendergast JG; Barnetson RA; Cetnarskyj R; Porteous ME; Pharoah PD; Koessler T; Hampe J; Buch S; Schafmayer C; Tepel J; Schreiber S; Völzke H; Chang-Claude J; Hoffmeister M; Brenner H; Zanke BW; Montpetit A; Hudson TJ; Gallinger S; Campbell H; Dunlop MG
Nat Genet; 2008 Dec; 40(12):1426-35. PubMed ID: 19011631
[TBL] [Abstract][Full Text] [Related]
30. Genome-wide investigation of gene-environment interactions in colorectal cancer.
Siegert S; Hampe J; Schafmayer C; von Schönfels W; Egberts JH; Försti A; Chen B; Lascorz J; Hemminki K; Franke A; Nothnagel M; Nöthlings U; Krawczak M
Hum Genet; 2013 Feb; 132(2):219-31. PubMed ID: 23114982
[TBL] [Abstract][Full Text] [Related]
31. A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancer.
Matsuyama T; Kandimalla R; Ishikawa T; Takahashi N; Yamada Y; Yasuno M; Kinugasa Y; Hansen TF; Fakih M; Uetake H; Győrffy B; Goel A
Int J Cancer; 2020 Dec; 147(11):3250-3261. PubMed ID: 32657428
[TBL] [Abstract][Full Text] [Related]
32. CDH1 polymorphisms and haplotypes in sporadic diffuse and intestinal gastric cancer: a case-control study based on direct sequencing analysis.
Chu CM; Chen CJ; Chan DC; Wu HS; Liu YC; Shen CY; Chang TM; Yu JC; Harn HJ; Yu CP; Yang MH
World J Surg Oncol; 2014 Mar; 12():80. PubMed ID: 24684952
[TBL] [Abstract][Full Text] [Related]
33. Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis.
Sanz-Pamplona R; Melas M; Maoz A; Schmit SL; Rennert H; Lejbkowicz F; Greenson JK; Sanjuan X; Lopez-Zambrano M; Alonso MH; Qu C; McDonnell KJ; Idos GE; Vignali M; Emerson R; Fields P; Guinó E; Santos C; Salazar R; Robins HS; Rennert G; Gruber SB; Moreno V
PLoS Med; 2020 Sep; 17(9):e1003292. PubMed ID: 32970670
[TBL] [Abstract][Full Text] [Related]
34. Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry.
Trinh A; Trumpi K; De Sousa E Melo F; Wang X; de Jong JH; Fessler E; Kuppen PJ; Reimers MS; Swets M; Koopman M; Nagtegaal ID; Jansen M; Hooijer GK; Offerhaus GJ; Kranenburg O; Punt CJ; Medema JP; Markowetz F; Vermeulen L
Clin Cancer Res; 2017 Jan; 23(2):387-398. PubMed ID: 27459899
[TBL] [Abstract][Full Text] [Related]
35. An immune, stroma, and epithelial-mesenchymal transition-related signature for predicting recurrence and chemotherapy benefit in stage II-III colorectal cancer.
Cai D; Wang W; Zhong ME; Fan D; Liu X; Li CH; Huang ZP; Zhu Q; Lv MY; Hu C; Duan X; Wu XJ; Gao F
Cancer Med; 2023 Apr; 12(7):8924-8936. PubMed ID: 36629124
[TBL] [Abstract][Full Text] [Related]
36. Association of common genetic variants with colorectal cancer risk in a Romanian sample.
Mateş IN; Csiki I; Mateş D; Constantinescu V; Badea P; Dinu D; Constantin A; Constantinoiu S
Chirurgia (Bucur); 2010; 105(6):749-57. PubMed ID: 21351697
[TBL] [Abstract][Full Text] [Related]
37. Roles of E-cadherin (CDH1) genetic variations in cancer risk: a meta-analysis.
Deng QW; He BS; Pan YQ; Sun HL; Xu YQ; Gao TY; Li R; Song GQ; Wang SK
Asian Pac J Cancer Prev; 2014; 15(8):3705-13. PubMed ID: 24870781
[TBL] [Abstract][Full Text] [Related]
38. Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance).
Innocenti F; Sibley AB; Patil SA; Etheridge AS; Jiang C; Ou FS; Howell SD; Plummer SJ; Casey G; Bertagnolli MM; McLeod HL; Auman JT; Blanke CD; Furukawa Y; Venook AP; Kubo M; Lenz HJ; Parker JS; Ratain MJ; Owzar K
Clin Cancer Res; 2021 Jan; 27(1):267-275. PubMed ID: 32958699
[TBL] [Abstract][Full Text] [Related]
39. Validation of Genetic Markers Associated with Survival in Colorectal Cancer Patients Treated with Oxaliplatin-Based Chemotherapy.
Park HA; Seibold P; Edelmann D; Benner A; Canzian F; Alwers E; Jansen L; Schneider M; Hoffmeister M; Brenner H; Chang-Claude J
Cancer Epidemiol Biomarkers Prev; 2022 Feb; 31(2):352-361. PubMed ID: 34862210
[TBL] [Abstract][Full Text] [Related]
40. A 16q22.1 variant confers susceptibility to colorectal cancer as a distal regulator of ZFP90.
Yu CY; Han JX; Zhang J; Jiang P; Shen C; Guo F; Tang J; Yan T; Tian X; Zhu X; Ma D; Hu Y; Xie Y; Du W; Zhong M; Chen J; Liu Q; Sun D; Chen Y; Zou W; Hong J; Chen H; Fang JY
Oncogene; 2020 Feb; 39(6):1347-1360. PubMed ID: 31641208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
